106 related articles for article (PubMed ID: 7191299)
1. [Effect of glucosidase inhibitor, Bay g 5421 (acarbose), on the blood glucose in obese diabetic patients ty pe 2 (NIDDM) (author's transl)].
Laube H; Fouladfar M; Aubell R; Schmitz H
Arzneimittelforschung; 1980; 30(7):1154-7. PubMed ID: 7191299
[TBL] [Abstract][Full Text] [Related]
2. Effects of an alpha-glucosidase inhibitor, acarbose, on blood glucose and serum lipids in streptozotocin-induced diabetic rats.
Yamashita K; Sugawara S; Sakairi I
Horm Metab Res; 1984 Apr; 16(4):179-82. PubMed ID: 6373545
[TBL] [Abstract][Full Text] [Related]
3. Effect of a glucosidase inhibitor on the metabolic response of diabetic rats to a high carbohydrate diet, consisting of starch and sucrose, or glucose.
Gray RS; Olefsky JM
Metabolism; 1982 Jan; 31(1):88-92. PubMed ID: 7043164
[TBL] [Abstract][Full Text] [Related]
4. [Effect of acarbose on postprandial increase in blood glucose. Additive acute effect of once daily administration in insulin treated diabetes].
Ledermann H; Höxter G
Fortschr Med; 1994 Nov; 112(32):467-70. PubMed ID: 7821886
[TBL] [Abstract][Full Text] [Related]
5. Effects of alpha-glucosidase inhibitor (acarbose) combined with sulfonylurea or sulfonylurea and metformin in treatment of non-insulin-dependent diabetes mellitus.
Vannasaeng S; Ploybutr S; Nitiyanant W; Peerapatdit T; Vichayanrat A
J Med Assoc Thai; 1995 Nov; 78(11):578-85. PubMed ID: 8576667
[TBL] [Abstract][Full Text] [Related]
6. The addition of acarbose to insulin lispro reduces acute glycaemic responses in patients with type-2 diabetes.
Hermanns N; Burkert A; Haak T
Exp Clin Endocrinol Diabetes; 2004 Jun; 112(6):310-4. PubMed ID: 15216448
[TBL] [Abstract][Full Text] [Related]
7. [Clinical experience with an alpha glucosidase inhibitor (acarbose) in the treatment of non-insulin-dependent diabetes. Multicenter study].
García de los Ríos M; Mujica V; Muñoz S; Durruty P; Larenas G; López MI; Kuzmanic A; Pérez J; Flaskamp R; Cumsille F
Rev Med Chil; 1997 Aug; 125(8):856-62. PubMed ID: 9580485
[TBL] [Abstract][Full Text] [Related]
8. Effects of acarbose, an alpha-glucosidase inhibitor (Bay G 5421), on orally loaded glucose, maltose and sucrose and on blood glucose control in non-insulin-dependent diabetics.
Hayakawa T; Noda A; Kondo T; Okumura N
Nagoya J Med Sci; 1985 Jan; 47(1-2):35-41. PubMed ID: 3887176
[No Abstract] [Full Text] [Related]
9. [Evaluation of acarbose efficacy and safety for treatment of diabetes mellitus. Testing of observations under general health care conditions].
Sieradzki J; Soszyński P
Przegl Lek; 1999; 56(5):335-41. PubMed ID: 10554569
[TBL] [Abstract][Full Text] [Related]
10. Effects of the alpha-glucosidase inhibitor acarbose on postprandial serum glucose and insulin concentrations in healthy dogs.
Robertson J; Nelson R; Kass P; Neal L
Am J Vet Res; 1999 May; 60(5):541-5. PubMed ID: 10328421
[TBL] [Abstract][Full Text] [Related]
11. [Modification of carbohydrate metabolism and oral glucose tolerance test in type II diabetics using the glucosidase inhibitor acarbose].
Schwartzkopff W; Calder D
Med Welt; 1984 Feb; 35(6):169-74. PubMed ID: 6369065
[No Abstract] [Full Text] [Related]
12. Effect of exenatide on 24-hour blood glucose profile compared with placebo in patients with type 2 diabetes: a randomized, double-blind, two-arm, parallel-group, placebo-controlled, 2-week study.
Schwartz SL; Ratner RE; Kim DD; Qu Y; Fechner LL; Lenox SM; Holcombe JH
Clin Ther; 2008 May; 30(5):858-67. PubMed ID: 18555933
[TBL] [Abstract][Full Text] [Related]
13. Effect of acarbose (BAY-g-5421) on expression of noninsulin-dependent diabetes mellitus in sucrose-fed SHR/N-corpulent rats.
Carswell N; Michaelis OE; Prather ES
J Nutr; 1989 Mar; 119(3):388-94. PubMed ID: 2646401
[TBL] [Abstract][Full Text] [Related]
14. [Effectiveness and tolerance of long-term acarbose therapy in diabetic patients with threatened secondary failure of sulfonylurea drug treatment].
Domke A; Willms B
Med Klin (Munich); 1994 Apr; 89(4):187-92. PubMed ID: 8015532
[TBL] [Abstract][Full Text] [Related]
15. Reduction of glycosylated hemoglobin and postprandial hyperglycemia by acarbose in patients with NIDDM. A placebo-controlled dose-comparison study.
Coniff RF; Shapiro JA; Robbins D; Kleinfield R; Seaton TB; Beisswenger P; McGill JB
Diabetes Care; 1995 Jun; 18(6):817-24. PubMed ID: 7555508
[TBL] [Abstract][Full Text] [Related]
16. Miglitol suppresses the postprandial increase in interleukin 6 and enhances active glucagon-like peptide 1 secretion in viscerally obese subjects.
Arakawa M; Ebato C; Mita T; Fujitani Y; Shimizu T; Watada H; Kawamori R; Hirose T
Metabolism; 2008 Sep; 57(9):1299-306. PubMed ID: 18702958
[TBL] [Abstract][Full Text] [Related]
17. Effect of acarbose in treatment of type II diabetes mellitus: a double-blind, crossover, placebo-controlled trial.
Soonthornpun S; Rattarasarn C; Thamprasit A; Leetanaporn K
J Med Assoc Thai; 1998 Mar; 81(3):195-200. PubMed ID: 9623011
[TBL] [Abstract][Full Text] [Related]
18. The effects of the alpha-glucosidase inhibitor BAY g 5421 (Acarbose) on meal-stimulated elevations of circulating glucose, insulin, and triglyceride levels in man.
Hillebrand I; Boehme K; Frank G; Fink H; Berchtold P
Res Exp Med (Berl); 1979 Apr; 175(1):81-6. PubMed ID: 375342
[TBL] [Abstract][Full Text] [Related]
19. The effects of the alpha-glucosidase inhibitor BAY g 5421 (Acarbose) on postprandial blood glucose, serum insulin, and triglyceride levels: dose-time-response relationships in man.
Hillebrand I; Boehme K; Frank G; Fink H; Berchtold P
Res Exp Med (Berl); 1979 Apr; 175(1):87-94. PubMed ID: 375343
[TBL] [Abstract][Full Text] [Related]
20. A double-blind study on the efficacy and tolerance of a new alpha-glucosidase inhibitor in type-2 diabetics.
Katsilambros N; Philippides P; Toskas A; Protopapas J; Frangaki D; Marangos M; Siskoudis P; Anastasopoulou K; Xefteri H; Hillebrand I
Arzneimittelforschung; 1986 Jul; 36(7):1136-8. PubMed ID: 3533089
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
